Denifanstat
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Denifanstat
- Molecular weight
- 439.56
- Structure (SMILES)
- Cc1nc(-c2cc(C(=O)N3CCC(c4ccc(C#N)cc4)CC3)c(C)cc2C2CCC2)n[nH]1
- asc 40
- ASC-40
- denifanstat
- Denifanstat
- denifanstat [INN]
- DENIFANSTAT [USAN]
- denifanstat inn
- denifanstat usan
- tvb 2640
- Tvb 2640
- TVB 2640 [WHO-DD]
- tvb 2640 who dd
- TVB-2640
- TVB-2640 - 50 mg
- TVB-2640 25 mg (US)
- TVB-2640 50 mg (China)
- TVB-2640 50 mg (US)
- TVB-2640 75 mg (US)
- CAS registry numbers
- 1399177-37-7
- ChEMBL ID
- CHEMBL3661754
- InChIKey
- BBGOSBDSLYHMRA-UHFFFAOYSA-N
- PubChem compound IDs
- 66548316
- FDA ingredient codes (UNII)
- 4GF95B2LZA
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- denifanstat
- Type
- Synthetic organic
- Drug name stem
- -stat
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- fatty acid synthase
- Gene symbol
- FASN
- Protein identifier
- P49327
- Median affinity
- 7.28
- Affinity units
- pIC50
- Condition
- Astrocytoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000272
- Subject identifier
- D001254
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000305
- Subject identifier
- D001943
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Non-alcoholic Fatty Liver Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003095
- Subject identifier
- D065626
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Colonic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0021063
- Subject identifier
- D003110
- Condition identifier
- EFO_0000272
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000673
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003095
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003894
- Highest recorded phase
- 3
- Condition identifier
- EFO_0006890
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001950
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007027
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0011438
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0013209
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0018177
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0019781
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0021063
- Highest recorded phase
- 2
- NCT02223247
- NCT02980029
- NCT03032484
- NCT03179904
- NCT03938246
- NCT04906421
- NCT05743621
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 1
- Polar surface area
- 85.67
- Calculated partition coefficient (ALogP)
- 5.25
- Calculated partition coefficient (XLogP)
- 5.3
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 4
- Heavy atoms
- 33
- Molecular formula
- C27H29N5O
- Monoisotopic mass
- 439.23721057
- Natural product
- No
- Recorded assays
- 6
- Active assays
- 5
Active assay types
- Confirmatory
Related records
Trials (33)
- A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants
- A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors
- A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
- A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH
- A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
- A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC
- A Study to Assess Clinical Gingivitis and Microbiome Following the Use of Multiple Oral Hygiene Products
- A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®
- A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC
- Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects
- Bioequivalence Study of Dapagliflozin 10 mg Film-coated Tablets
- Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
- Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma
- Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
- Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
- Effect of Dapagliflozin Administration on the Apoptosis Levels of Patients With Acute Myocardial Infarction
- Effect of Photodynamic Therapy on Soft Tissue Healing After Tooth Extraction at Sites of Periodontal Infection
- Efficacy and Safety of Liuwei Dihuang Pill Versus Placebo in Presbycusis With Shen (Kidney)-Yin Deficiency
- Electroacupuncture for PHN: Efficacy and Biomarker Evaluation in a Multicenter, Randomized, Sham-Controlled Trial Protocol
- Hyperthermia Combined With Immune Checkpoint Inhibitor Therapy for Advanced Gastrointestinal Tumours
In development for (9)
- Acne Phase 3
- Astrocytoma (excluding glioblastoma) Phase 2
- Breast carcinoma Phase 2
- Cancer Phase 1
- Colon carcinoma Phase 2
- Malignant colon neoplasm Phase 1
- Metabolic dysfunction-associated steatotic liver disease Phase 2
- Neoplasm Phase 1
- Prostate adenocarcinoma Phase 1